MICROSATELLITE STABLE COLORECTAL CANCER
Clinical trials for MICROSATELLITE STABLE COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new MICROSATELLITE STABLE COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for MICROSATELLITE STABLE COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Matched conditions: MICROSATELLITE STABLE COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Matched conditions: MICROSATELLITE STABLE COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…
Matched conditions: MICROSATELLITE STABLE COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for advanced colon cancer: immune drug shrinks tumors in genetic subtype
Disease control CompletedThis study tested whether the immunotherapy drug nivolumab, alone or with other drugs, can shrink tumors in people with colon cancer that has returned or spread. It included 385 participants whose tumors had a specific genetic feature called MSI-H or were non-MSI-H. The goal was …
Matched conditions: MICROSATELLITE STABLE COLORECTAL CANCER
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC